Ongoing research focusing on ARID1A and PI3K/AKT for the treatment of TNBC, by restoring ARID1A expression and inhibiting PI3K/AKT signaling, could successfully reduce tumor aggressiveness and improve the clinical outcomes in TNBC. Here, AKT1 is linked to neoplasm.